New arthritis drug candidate AZD6912 begins first human safety tests
NCT ID NCT06115967
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a single dose of the experimental drug AZD6912 in 40 healthy adults to see if it is safe and how the body processes it. The study is a first step toward possibly treating rheumatoid arthritis, but it does not involve people with the disease. Results will help decide whether to test the drug in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD6912
- What this could lead to
- If this drug is safe, it could lead to a new treatment option for rheumatoid arthritis.
- What could go wrong
- This is a very early Phase 1 trial in only 40 healthy people, not patients. It only tests safety and dosing, not whether the drug works for arthritis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Montreal, Quebec, H3P 3P1, Canada
-
Research Site
Harrow, HA1 3UJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?